Stifel Raises Price Target on Zumiez, Inc. (ZUMZ) to $18 Following Comp Sales Report
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Pre-Open Stock Movers 10/06: (ALQA) (SCYX) (ZUMZ) Higher; (ALNY) (TWTR) (MDCO) Lower (more...)
October 6, 2016 9:22 AM EDTToday's Pre-Open Stock Movers
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) 44.3% LOWER; announced that upon the recommendation of the ENDEAVOUR Phase 3 study Data Monitoring Committee (DMC) to suspend dosing, the Company has decided to discontinue development of revusiran, an investigational RNA interference (RNAi) therapeutic that was being developed for the treatment of hereditary ATTR amyloidosis with cardiomyopathy (hATTR-CM). This decision was made yesterday evening and has been communicated to investigators, study sites, and regulatory authorities.
Wedbush Raises Price Target on Zumiez, Inc. (ZUMZ) to $18; Reiterates Neutral
October 6, 2016 7:58 AM EDTWedbush reiterated a Neutral rating on Zumiez, Inc. (NASDAQ: ZUMZ), and raised the price target to $18.00 (from $15.00), as September sales come in better than expected. ZUMZ reported sales up 6.3% versus consensus expectations for a 1% decline. Positive sales were driven by mens, accessories, and juniors. 3Q sales were guided up to $216- $217 million up from $209-$213 million (versus consensus of... More
William Blair Upgrades Zumiez, Inc. (ZUMZ) to Outperform
October 6, 2016 7:30 AM EDTWilliam Blair upgraded Zumiez, Inc. (NASDAQ: ZUMZ) from Market Perform to Outperform.
For an analyst ratings summary and ratings history on Zumiez, Inc. click here. For more ratings news on Zumiez, Inc. click here.
Shares of Zumiez, Inc. closed at $18.27 yesterday.
... MoreB. Riley Upgrades Zumiez, Inc. (ZUMZ) to Buy
October 6, 2016 7:28 AM EDTB. Riley upgraded Zumiez, Inc. (NASDAQ: ZUMZ) from Neutral to Buy with a price target of $25.00.
For an analyst ratings summary and ratings history on Zumiez, Inc. click here. For more ratings news on Zumiez, Inc. click here.
Shares of Zumiez, Inc. closed at $18.27 yesterday.
... MoreAfter-Hours Stock Movers 10/05: (SCYX) (ZUMZ) (JD) Higher; (ALNY) (IDRA) (MDCO) Lower (more...)
October 5, 2016 6:10 PM EDTToday's After-Hours Movers
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) 42.3% LOWER; announced that upon the recommendation of the ENDEAVOUR Phase 3 study Data Monitoring Committee (DMC) to suspend dosing, the Company has decided to discontinue development of revusiran, an investigational RNA interference (RNAi) therapeutic that was being developed for the treatment of hereditary ATTR amyloidosis with cardiomyopathy (hATTR-CM). This decision was made yesterday evening and has been communicated to investigators, study sites, and regulatory authorities.
Zumiez, Inc. (ZUMZ) Comps Increased 6.3% in Sept.; Raises Q3 Guidance
October 5, 2016 4:02 PM EDTZumiez Inc. (NASDAQ: ZUMZ) announced that total net sales for the five-week period ended October 1, 2016 increased 11.5% to $75.0 million, compared to $67.3 million for the five-week period ended October 3, 2015. The Company's comparable sales increased 6.3% for the five-week period compared to a comparable sales decrease of... More
